Multiple Sclerosis (MS) News, Research Studies | MS Research Articles

Multiple Sclerosis


Featured Article

Latest News

FDA Approves Shorter Infusion Time for MS Drug Ocrevus

The approval was based on data from the phase 3b ENSEMBLE PLUS study that compared the frequency and severity of infusion-related reactions for a 2-hour Ocrevus infusion time to the previously approved 3.5-hour infusion time in patients with relapsing-remitting MS.
Next post in Multiple Sclerosis